Edition:
United States

Profile: Aeglea Bio Therapeutics Inc (AGLE.A)

AGLE.A on American Stock Exchange

8.19USD
21 Aug 2019
Change (% chg)

$0.14 (+1.74%)
Prev Close
$8.05
Open
$8.19
Day's High
$8.19
Day's Low
$8.19
Volume
100
Avg. Vol
323
52-wk High
$11.11
52-wk Low
$6.09

Aeglea BioTherapeutics, Inc., incorporated on December 16, 2013, is a biotechnology company. The Company is engaged in the development of enzyme-based therapeutics in the field of amino acid metabolism to treat inborn errors of metabolism (IEM) and cancer. Its engineered human enzymes are designed to reduce the level of specific amino acids in the blood. In IEM, it is seeking to reduce the toxic levels of amino acids in patients. The Company's product pipeline includes AEB1102, AEB3103, AEB2109 and AEB4104. Its products focus on degrading specific elements within the human metabolism. Its lead product candidate, AEB1102, is engineered to degrade the amino acid arginine and is being developed to treat over two extremes of arginine metabolism, including arginine excess in patients with Arginase I deficiency, an IEM, as well as some cancers, which have shown to have a metabolic dependence on arginine. AEB1102 reduces blood arginine levels in nonclinical and oncology clinical studies supporting its use as a potential treatment of both Arginase I deficiency and those cancers predicted to be dependent on arginine for survival.

The Company has initiated over three Phase I clinical trials for AEB1102. It also has initiated enrollment for a dose escalation trial in patients with advanced solid tumors. It also initiated a clinical trial in patients with relapsed refractory acute myeloid leukemia (AML), and myelodysplastic syndrome (MDS) in the United States and Canada. The Company announced the dosing of the first patient in a Phase I trial of AEB1102 for the treatment of hematological malignancies, AML and MDS. The Company's engineered human enzyme product candidates in nonclinical development include AEB4104, AEB2109 and AEB3103. AEB3103 targets the degradation of the amino acid cysteine/cystine. AEB2109 targets the degradation of the amino acid methionine. AEB4104 targets the reduction of elevated levels of the amino acid homocystine associated with the IEM classical homocystinuria.

The Company competes with Horizon Pharma plc and Polaris Pharmaceuticals.

Company Address

Aeglea Bio Therapeutics Inc

901 S. Mopac Expressway
Ste. 250, Barton Oaks Plaza One
AUSTIN   TX   78746
P: +1512.9422935
F: +1512.8725121

Company Web Links